Launchbio Inc.

“Draft of form 990 is provided to the board of directors for review prior to filing.”

“Launchbio's conflict of interest policy is located in the organization's bylaws. The bylaws require regular and consistent disclosure of all potential conflicts in addition to compliance and enforcement of the policy.”

“Compensation for the ceo is determined by the board of directors after review of compensation studies.”

“Form 990 returns are made available to the public upon request.”

“Corporate documents are made available to the public upon request.”

“In 2024, launchbio continued to execute its mission through a robust slate of programs and initiatives, expanding its national footprint and deepening its impact within the biotechnology sector. Key activities included: 1. Program expansion larger than life science series: launchbio hosted its signature "larger than life science" in-person event series across multiple biotech hubs, including durham, san diego, and cambridge. In 2024, the series brought together entrepreneurs, investors, and industry experts for workshops, panel discussions, and networking. Topics covered emerging trends such as biomanufacturing innovations, gene therapy commercialization, and data security for startups, equipping over 1,200 participants with actionable insights and connections to scale their ventures. 2. Invest in cures forum: the annual "invest in cures" forum, held in february 2024 in collaboration with uc san francisco and convened leaders from disease foundations, social venture funds, and biotech startups. This flagship event facilitated discussions on accelerating early-stage therapies, with a focus on rare diseases, and had 150 attendees. The forum underscored launchbio's role in bridging capital and innovation. 3. Investor connect: building on its networking mission, launchbio expanded the "investor connect" initiative in 2024, hosting 12 virtual events. These events connected over 120 early-stage biotech founders with venture capitalists in curated, application based meetings. The results bridged innovators to capital in a way that was previously not being done. 4. Strategic partnerships and regional impact: launchbio strengthened its collaboration with partners like biolabs and the u.s. Economic development administration, leveraging a 2023 "build to scale" grant to enhance the biotech+ hub at pegasus park. In 2024, this hub became a cornerstone for north texas biotech innovation, onboarding 10 new resident companies and launching a training program for underrepresented high school students, with over 250 participants gaining real world experience as biotech entrepreneurs. 5. Virtual programming and thought leadership: launchbio delivered 5 webinars in 2024, including the "going virtual" series and "nextgen vc" podcast, reaching a global audience of 3,000+ biotech professionals. These programs provided insights into venture capital trends, equity management, and compensation strategies (e.g., featuring experts like jody thelander), reinforcing launchbio's role as an educational leader in the field. These activities reflect launchbio's ongoing commitment to empowering biotech entrepreneurs and driving innovation, with measurable outcomes in ecosystem connectivity, startup growth, and community engagement throughout 2024.”

“Payroll processing fees: program service expenses 1,009. Management and general expenses 1,009. Fundraising expenses 0. Total expenses 2,018. Contracted staff: program service expenses 41,107. Management and general expenses 41,107. Fundraising expenses 0. Total expenses 82,214. Contracted marketing & public relations: program service expenses 44,432. Management and general expenses 44,431. Fundraising expenses 0. Total expenses 88,863.”